Skip to main content
SpringerLink
Log in
Book cover

Vascular Diseases for the Non-Specialist pp 233–251Cite as

Clinical Treatment of Vascular Diseases

  • Chapter
  • First Online:

  • 962 Accesses

Abstract

Clinical treatment of vascular disease holds several pathologies and their risk factors. The most important are arterial obstructive disease, aortic aneurysm, and acute aortic syndrome.

Obstructive vascular disease reaches all arterial territories, with atherosclerosis as the most important cause. In peripheral artery disease, obstruction of limb arteries will determine the presence of symptoms, such as intermittent claudication and critical limb ischemia (rest pain, gangrene, or ulcers). Clinical management of obstructive disease includes control of risk factors and symptomatic relief, prevention of cardiovascular events and improvement of functional capacity.

The aortic aneurysm and acute aortic syndrome are complex pathologies of aorta. The main goal of medical therapy in aortic aneurysm and acute aortic syndrome is to decrease shear stress on aortic wall (thus reducing rupture and growing rates) and inflammation process since there is a direct relation between diameter, grown and rupture rates.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   119.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Buch MH, Prendergast BD, Storey RF. Antiplatelet therapy and vascular disease: an update. Ther Adv Cardiovasc Dis. 2010;4:249–75.

    Article  CAS  PubMed  Google Scholar 

  2. Solomon CG, Kullo IJ, Rooke TW. Peripheral artery disease. N Engl J Med. 2016;374:861–71.

    Article  Google Scholar 

  3. Tangelder MJD, van Hattum ES. Antithrombotic therapy in peripheral artery disease—antiplatelet therapy, anticoagulants, both or none. Thromb Haemost. 2010;104:196–9.

    Article  CAS  PubMed  Google Scholar 

  4. Singer DRJ, Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter? Eur J Vasc Endovasc Surg. 2008;35:701–8.

    Article  CAS  PubMed  Google Scholar 

  5. Qian J, Yang XH. A meta-analysis of randomized controlled trials on antiplatelet agents versus placebo/control for treating peripheral artery disease. Medicine. 2015;94:e1293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Di Minno G, et al. Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Ann Med. 2014;46:475–89.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Katsanos K, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS One. 2015;10:e0135692.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral artery disease. J Am Coll Cardiol. 2016;67:1338–57.

    Article  PubMed  Google Scholar 

  9. Stoyioglou A, Jaff MR. Medical treatment of peripheral arterial disease: a comprehensive review. J Vasc Interv Radiol. 2004;15:1197–207.

    Article  PubMed  Google Scholar 

  10. Bedenis R, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014;10:CD003748.

    Google Scholar 

  11. Vemulapalli S, Patel MR, Jones WS. Limb ischemia: cardiovascular diagnosis and management from head to toe. Curr Cardiol Rep. 2015;17:57.

    Article  Google Scholar 

  12. Elsayed S, Clavijo LC. Critical limb ischemia. Cardiol Clin. 2015;33:37–47.

    Article  PubMed  Google Scholar 

  13. Violi F, Basili S, Berger JS, Hiatt WR. Handbook of experimental pharmacology, vol. 210. Berlin: Springer; 2012. p. 547–63.

    Google Scholar 

  14. Barter P, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.

    Article  CAS  PubMed  Google Scholar 

  15. Developed with the special contribution of: European Association for Cardiovascular Prevention & Rehabilitation, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–818.

    Google Scholar 

  16. Anderson TJ, et al. 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29:151–67.

    Article  PubMed  Google Scholar 

  17. Ray KK, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35:960–8.

    Article  PubMed  Google Scholar 

  18. Endorsed by: the European Stroke Organisation (ESO), et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2851–906.

    Google Scholar 

  19. Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86:484–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–87.

    Article  CAS  PubMed  Google Scholar 

  21. Ridker PM, Cook NR. Comment statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;1–4. doi:10.1016/S0140-6736(13)62388-0.

  22. Lumsden AB, Davies MG, Peden EK. Medical and endovascular management of critical limb ischemia. J Endovasc Ther. 2009;16(2 Suppl 2):II31–62.

    PubMed  Google Scholar 

  23. Fellström BC, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.

    Article  PubMed  Google Scholar 

  24. Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

    Article  CAS  PubMed  Google Scholar 

  25. Longo DL, Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374:664–9.

    Article  Google Scholar 

  26. Sattar N, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.

    Article  CAS  PubMed  Google Scholar 

  27. Collaboration CTTC. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.

    Article  Google Scholar 

  28. Collaborators CTTC. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.

    Article  Google Scholar 

  29. Authors/Task Force Members, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33:1635–701.

    Google Scholar 

  30. Boekholdt SM, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–9.

    Article  CAS  PubMed  Google Scholar 

  31. Conte MS, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61:1–40. doi:10.1016/j.jvs.2014.12.009.

    Article  Google Scholar 

  32. Schulte JM, Rothaus CS, Adler JN. Starting statins—polling results. N Engl J Med. 2014;371:e6.

    Article  PubMed  Google Scholar 

  33. Stone N. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. 2013;1–85. doi:10.1161/01.cir.0000437738.63853.7a/-/DC1.

  34. Schouten O, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361:980–9.

    Article  CAS  PubMed  Google Scholar 

  35. Wanner C, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.

    Article  CAS  PubMed  Google Scholar 

  36. Baigent C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Athyros VG, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916–22.

    Article  CAS  PubMed  Google Scholar 

  38. Kinlay S. Management of critical limb ischemia. Circ Cardiovasc Interv. 2016;9:e001946.

    Article  CAS  PubMed  Google Scholar 

  39. LaRosa JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.

    Article  CAS  PubMed  Google Scholar 

  40. Nicholls SJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078–87.

    Article  CAS  PubMed  Google Scholar 

  41. Cheng JWM. Updates in antiplatelet agents used in cardiovascular diseases. J Cardiovasc Pharmacol Ther. 2013;18:514–24.

    Article  CAS  PubMed  Google Scholar 

  42. Manolis AS, Tzeis S, Andrikopoulos G, Koulouris S, Melita H. Aspirin and clopidogrel: a sweeping combination in cardiology. Curr Med Chem Cardiovasc Hematol Agents. 2005;3:203–19.

    Article  CAS  PubMed  Google Scholar 

  43. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

    Google Scholar 

  44. Wong PF, Chong LY, Mikhailidis DP, Robless P, Stansby G. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev. 1996;(11):CD001272. doi:10.1002/14651858.CD001272.pub2.

  45. Wood A, Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330(18):1287–94.

    Article  Google Scholar 

  46. Clappers N, Brouwer MA, Verheugt FWA. Antiplatelet treatment for coronary heart disease. Heart. 2005;93:258–65.

    Article  Google Scholar 

  47. Vidal SGM, Ruland S. Platelet antiaggregants in stroke prevention. Neurol Clin North Am. 2013;31:633–57.

    Article  Google Scholar 

  48. Seshasai SRK. Effect of aspirin on vascular and nonvascular outcomes. Arch Intern Med. 2012;172:209.

    Article  CAS  PubMed  Google Scholar 

  49. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–39.

    Google Scholar 

  50. Savi P, Nurden P, Nurden AT, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets. 1998;9:251–5.

    Article  CAS  PubMed  Google Scholar 

  51. Berger PB, et al. bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial. Circulation. 2010;121:2575–83.

    Article  CAS  PubMed  Google Scholar 

  52. Mauri L, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–66.

    Article  PubMed  PubMed Central  Google Scholar 

  53. The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817–25.

    Google Scholar 

  54. Lambert MA, Belch JJF. Medical management of critical limb ischaemia: where do we stand today? J Intern Med. 2013;274:295–307.

    Article  CAS  PubMed  Google Scholar 

  55. Fowkes F, Price JF, Stewart M, Butcher I. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–8.

    Article  CAS  PubMed  Google Scholar 

  56. van Vark LC, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33:2088–97.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4:42–50.

    Google Scholar 

  58. Shahin Y, Khan JA, Samuel N, Chetter I. Atherosclerosis. Atherosclerosis. 2011;216:7–16.

    Article  CAS  PubMed  Google Scholar 

  59. Treatment of hypertension in peripheral arterial disease (Review). 2013;1–48.

    Google Scholar 

  60. Paravastu SCV, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease (Review). 2012;1–32.

    Google Scholar 

  61. Bailey M, Griffin K, Scott D. Clinical assessment of patients with peripheral arterial disease. Semin Intervent Radiol. 2014;31:292–9.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Agrawal K, Eberhardt RT. Contemporary medical management of peripheral arterial disease. Cardiol Clin. 2015;33:111–37.

    Article  PubMed  Google Scholar 

  63. Knepper JP, Henke PK. Diagnosis, prevention, and treatment of claudication. Surg Clin North Am. 2013;93:779–88.

    Article  PubMed  Google Scholar 

  64. Rogers KC, Oliphant CS, Finks SW. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015;75:377–95.

    Article  CAS  PubMed  Google Scholar 

  65. Nicolaï SP, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 1996;(6):CD006888. doi:10.1002/14651858.CD006888.pub3.

  66. Nienaber CA, Powell JT. Management of acute aortic syndromes. Eur Heart J. 2012;33:26–35.

    Article  PubMed  Google Scholar 

  67. Thrumurthy SG, Karthikesalingam A, Patterson BO, Holt PJE, Thompson MM. The diagnosis and management of aortic dissection. BMJ. 2012;344:d8290.

    Article  Google Scholar 

  68. Erbel R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35:2873–926.

    Article  PubMed  Google Scholar 

  69. Karthikesalingam A, Holt PJE, Hinchliffe RJ, Thompson MM, Loftus IM. The diagnosis and management of aortic dissection. Vasc Endovasc Surg. 2010;44:165–9.

    Article  CAS  Google Scholar 

  70. Moll FL, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg. 2011;41:S1–58.

    Article  PubMed  Google Scholar 

  71. Goldfinger JZ, et al. Thoracic aortic aneurysm and dissection. J Am Coll Cardiol. 2014;64:1725–39.

    Article  PubMed  Google Scholar 

  72. Danyi P, Elefteriades JA, Jovin IS. Medical therapy of thoracic aortic aneurysms: are we there yet? Circulation. 2011;124:1469–76.

    Article  PubMed  Google Scholar 

  73. Bobadilla J, Orr N, Minion D. Thoracoabdominal aortic aneurysm repair: current endovascular perspectives. Vasc Health Risk Manag. 2014;10:493. doi:10.2147/VHRM.S46452.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Elefteriades JA, Farkas EA. Thoracic aortic aneurysm. J Am Coll Cardiol. 2010;55:841–57.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cirurgia Vascular, SHIS QI 29 Conj 12 CS 09, Lago Sul, Brasilia, 71675-320, Brazil

    Joice Cristina Daltoé Inglez M.D.

Authors
  1. Joice Cristina Daltoé Inglez M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joice Cristina Daltoé Inglez M.D. .

Editor information

Editors and Affiliations

  1. Department of Vascular Surgery, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Tulio Pinho Navarro

  2. Yale Univ School Medicine, New Haven, Connecticut, USA

    Alan Dardik

  3. Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Daniela Junqueira

  4. Universidade Federal de Minas Gerais, Belo Horizone, Minas Gerais, Brazil

    Ligia Cisneros

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Inglez, J.C.D. (2017). Clinical Treatment of Vascular Diseases. In: Navarro, T., Dardik, A., Junqueira, D., Cisneros, L. (eds) Vascular Diseases for the Non-Specialist. Springer, Cham. https://doi.org/10.1007/978-3-319-46059-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-46059-8_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-46057-4

  • Online ISBN: 978-3-319-46059-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation